Payam Amini, MD | UniHealth

Offices

4 locations · Azul Vision Inc · Eghbali Medical Surgical Inc · North Valley Eye Medical Group Inc · California Eye Specialists Medical Group Inc

Looking this up.

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Amini’s office to ask if they take your plan before you enroll.

California Medical Board record

Licence A107595 · Current

Licensed to practise in California · since 2009 · expires 2027-03-31 · State University of New York Health Science Center at Syracuse.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

School, training and certification

What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.

Specialty certification

American Board of Ophthalmology - Ophthalmology

Original Medicare doctor bills

$729,918

Medicare paid this office $729,918 for 1,434 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Injection, aflibercept, 1 mg	20	$143,845	None
Return visit (30+ min)	711	$114,787	$90
Injection of drug into eye	271	$90,593	$90
Imaging of retina	734	$56,857	$31
Injection, bevacizumab, 10 mg	242	$56,314	None

See all 28 services

Sort by

Every Original Medicare service billed

Injection, aflibercept, 1 mg	20	$143,845	None
Return visit (30+ min)	711	$114,787	$90
Injection of drug into eye	271	$90,593	$90
Imaging of retina	734	$56,857	$31
Injection, bevacizumab, 10 mg	242	$56,314	None
Short return visit (20+ min)	405	$34,095	$61
Established patient complete exam of visual system	257	$31,324	$94
Established patient problem focused exam of visual system	182	$12,986	$61
Destruction of leaking blood vessels of retina using laser	20	$8,499	$293
New patient visit (45+ min)	85	$8,482	$100
Removal of recurring cataract in lens capsule using a laser	27	$7,151	$265
Photography of the retina	207	$6,551	$27
Exam of visual field with extended testing	118	$5,070	$42
New patient complete exam of visual system	60	$4,808	$80
Imaging of optic nerve	174	$4,353	$24
Long return visit (40+ min)	25	$3,203	$123
New patient visit (30+ min)	29	$2,188	$75
Exam of retinal blood vessels using a special camera after injection of a dye	11	$1,617	$135
2d ultrasound scan of eye tissue and structures	28	$1,297	$36
Ultrasound scan to determine eye length and lens power	21	$1,161	$27
Ct scan of cornea	49	$1,115	$23
Extended exam of the back part of the eye with optic nerve drawing	90	$1,086	$11
1d ultrasound scan of eye tissue and structures	24	$1,008	$42
Exam of visual field with intermediate testing	17	$625	$35
Short return visit	15	$624	$42
Measurement of corneal curvature and depth of eye	15	$501	$23
Exam of the internal drainage system of eye	16	$300	$18
Ultrasound scan of cornea to determine thickness	33	$208	$6

Procedures Medicare counted

Sort by

Procedure volume Medicare published

Cataract surgery	29	More than 52% of doctors who do this

Procedures year by year

Procedures billed to Original Medicare by year
Procedure	2019	2020	2021	2022	2023	2024
Injection of drug into eye	611	637	639	704	673	1,012
Destruction of leaking blood vessels of retina using laser	38	47	36	24	27	29
Removal of recurring cataract in lens capsule using a laser	–	–	–	15	25	27
Destruction of growth of retina using a laser	30	–	–	–	–	–
Closure of tear duct opening using plug	–	–	–	–	20	–
Removal of cataract with insertion of prosthetic lens	–	–	–	–	17	–

Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.

Who their Medicare patients are

1,434 Original Medicare patients in 2024. Average age 73 · Under 65 13% · 85 and older 12% · Women 59% · Also on Medicaid 56% · Health risk score 1.74. Sicker patients than 9 in 10 peers; the typical ophthalmology clinician is at 1.16.

Conditions among them: High blood pressure 75% · Diabetes 53% · Chronic kidney disease 34% · Coronary heart disease 25% · Depression 19% · Heart failure 17% · COPD 12% · Cancer 11% · Atrial fibrillation 11% · Dementia 7% · Stroke 7%.

The office billed $2,459,815, Medicare allowed $983,758 and paid $729,918; for 10,421 services of 70 kinds; $293,767 of it was for drugs given in the office and $436,151 for care.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	1,434	10,421	73	1.74	$2,459,815	$729,918
2023	1,154	6,578	73	1.63	$1,723,451	$565,815
2022	1,238	6,453	75	1.61	$1,572,843	$539,884
2021	784	5,115	75	1.61	$1,105,682	$448,415
2020	419	5,812	74	2.08	$906,183	$355,059
2019	500	7,043	75	1.88	$1,006,583	$408,652
2018	588	7,351	77	1.87	$1,397,288	$607,671
2017	602	6,709	77	1.82	$1,270,421	$570,298
2016	655	6,647	78	1.68	$1,235,763	$587,064
2015	511	3,890	76	2.14	$712,871	$298,640
2014	329	2,522	74	2.07	$493,361	$196,144
2013	231	1,125	73	2.02	$208,377	$70,015

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 25 services

Sort by

Original Medicare services billed in 2023

Return visit (30+ min)	674	$124,052	$100
Injection, aflibercept, 1 mg	18	$122,944	None
Injection of drug into eye	204	$66,036	$98
Imaging of retina	604	$45,437	$34
Injection, bevacizumab, 10 mg	184	$36,581	None
Short return visit (20+ min)	241	$26,273	$68
Established patient problem focused exam of visual system	112	$10,604	$77
New patient visit (45+ min)	88	$10,505	$119
Established patient complete exam of visual system	90	$9,617	$106
New patient complete exam of visual system	70	$8,154	$116
Destruction of leaking blood vessels of retina using laser	21	$7,998	$296
Removal of cataract with insertion of prosthetic lens	16	$7,498	$441
Removal of recurring cataract in lens capsule using a laser	21	$7,115	$285
Exam of visual field with extended testing	100	$4,877	$46
Imaging of optic nerve	136	$4,022	$28
Closure of tear duct opening using plug	13	$3,679	$184
Photography of the retina	100	$3,321	$29
Exam of retinal blood vessels using a special camera after injection of a dye	15	$1,550	$97
2d ultrasound scan of eye tissue and structures	26	$1,397	$40
Extended exam of the back part of the eye with optic nerve drawing	109	$1,372	$12
Ct scan of cornea	33	$872	$26
Ultrasound scan to determine eye length and lens power	11	$728	$32
Photography of content of eyes	19	$401	$21
Measurement of corneal curvature and depth of eye	12	$356	$25
Ultrasound scan of cornea to determine thickness	23	$201	$9

2022: 22 services

Sort by

Original Medicare services billed in 2022

Injection, aflibercept, 1 mg	20	$122,209	None
Return visit (30+ min)	627	$110,320	$100
Injection of drug into eye	194	$67,337	$96
Imaging of retina	674	$52,368	$34
Short return visit (20+ min)	398	$39,964	$69
Injection, bevacizumab, 10 mg	187	$36,734	None
Established patient problem focused exam of visual system	189	$13,743	$65
Established patient complete exam of visual system	108	$11,481	$103
New patient visit (45+ min)	94	$11,458	$122
Destruction of leaking blood vessels of retina using laser	16	$7,088	$295
Exam of visual field with extended testing	111	$5,358	$47
New patient complete exam of visual system	45	$4,849	$108
Photography of the retina	148	$4,725	$29
Imaging of optic nerve	156	$4,392	$27
Removal of recurring cataract in lens capsule using a laser	15	$3,977	$265
Exam of retinal blood vessels using a special camera after injection of a dye	28	$3,024	$104
Short return visit	59	$2,549	$38
Extended exam of the back part of the eye with optic nerve drawing	135	$2,139	$13
Ultrasound scan to determine eye length and lens power	31	$1,674	$54
Ct scan of cornea	37	$1,038	$27
Office for the evaluation and management of established patient that may not require presence of healthcare professional	38	$763	$20
Ultrasound scan of cornea to determine thickness	24	$207	$9

2021: 20 services

Sort by

Original Medicare services billed in 2021

Injection, aflibercept, 1 mg	13	$105,264	None
Injection of drug into eye	175	$61,161	$96
Imaging of retina	468	$43,039	$35
Return visit (30+ min)	298	$42,141	$111
Established patient complete exam of visual system	254	$36,648	$99
Injection, bevacizumab, 10 mg	154	$33,261	None
Short return visit (20+ min)	240	$29,979	$80
Established patient problem focused exam of visual system	168	$18,834	$74
Destruction of leaking blood vessels of retina using laser	19	$11,390	$316
New patient visit (45+ min)	33	$4,466	$135
Compounded drug, not otherwise classified	12	$4,061	None
New patient complete exam of visual system	28	$3,567	$127
Extended exam of the back part of the eye with optic nerve drawing	159	$3,224	$13
Exam of visual field with extended testing	45	$2,362	$52
Imaging of optic nerve	66	$2,096	$31
Exam of retinal blood vessels using a special camera after injection of a dye	15	$2,065	$109
Photography of the retina	60	$1,926	$29
2d ultrasound scan of eye tissue and structures	17	$1,246	$44
Short return visit	19	$956	$48
Extended exam of the back part of the eye with retinal drawing	26	$694	$20

2020: 14 services

Sort by

Original Medicare services billed in 2020

Injection, aflibercept, 1 mg	15	$68,012	None
Established patient complete exam of visual system	291	$64,719	$103
Injection of drug into eye	147	$53,788	$84
Imaging of retina	384	$39,598	$35
Injection, bevacizumab, 10 mg	127	$31,685	None
Established patient problem focused exam of visual system	166	$30,151	$76
Destruction of leaking blood vessels of retina using laser	16	$13,956	$297
Injection, triamcinolone acetonide, preservative free, 1 mg	17	$5,445	None
Return visit (30+ min)	44	$5,040	$90
Extended exam of the back part of the eye with optic nerve drawing	158	$2,808	$13
Extended exam of the back part of the eye with retinal drawing	75	$2,241	$22
Photography of the retina	40	$1,732	$39
New patient complete exam of visual system	14	$1,416	$101
Exam of retinal blood vessels using a special camera after injection of a dye	15	$1,258	$84

2019: 16 services

Sort by

Original Medicare services billed in 2019

Injection, aflibercept, 1 mg	15	$76,388	None
Established patient complete exam of visual system	337	$75,599	$103
Injection of drug into eye	150	$51,018	$83
Imaging of retina	468	$41,813	$35
Injection, bevacizumab, 10 mg	127	$29,394	None
Established patient problem focused exam of visual system	149	$27,263	$76
Examination of eye by ophthalmoscope with retinal drawing	274	$17,665	$22
Destruction of growth of retina using a laser	26	$13,394	$446
Return visit (30+ min)	92	$11,578	$90
Destruction of leaking blood vessels of retina using laser	18	$11,213	$295
Exam of retinal blood vessels using a special camera after injection of a dye	75	$7,261	$79
Injection, triamcinolone acetonide, preservative free, 1 mg	16	$6,468	None
Photography of the retina	93	$4,557	$41
New patient complete exam of visual system	19	$2,345	$123
2d ultrasound scan of eye tissue and structures	24	$1,775	$52
Examination of eye by ophthalmoscope with retinal drawing	39	$1,076	$24

2018: 16 services

Sort by

Original Medicare services billed in 2018

Injection, aflibercept, 1 mg	29	$202,565	None
Established patient complete exam of visual system	435	$114,417	$97
Injection of drug into eye	150	$54,113	$81
Imaging of retina	551	$46,998	$33
Injection, bevacizumab, 10 mg	128	$28,305	None
Examination of eye by ophthalmoscope with retinal drawing	364	$22,563	$20
Destruction of leaking blood vessels of retina using laser	24	$13,402	$274
Established patient problem focused exam of visual system	125	$13,286	$72
Exam of retinal blood vessels using a special camera after injection of a dye	122	$9,758	$68
Return visit (30+ min)	91	$9,298	$76
Destruction of growth of retina using a laser	17	$8,037	$423
Photography of the retina	155	$7,638	$44
2d ultrasound scan of eye tissue and structures	36	$4,136	$59
New patient complete exam of visual system	22	$2,422	$110
Exam of retinal blood vessels and blood vessels between the white part of eye and retina using a special camera after injection of a dye	11	$2,256	$205
Examination of eye by ophthalmoscope with retinal drawing	43	$1,540	$23

2017: 16 services

Sort by

Original Medicare services billed in 2017

Injection, aflibercept, 1 mg	32	$181,653	None
Established patient complete exam of visual system	441	$100,891	$96
Injection of drug into eye	146	$51,770	$83
Imaging of retina	549	$44,476	$30
Injection, ranibizumab, 0.1 mg	11	$43,820	None
Injection, bevacizumab, 10 mg	121	$26,920	None
Examination of eye by ophthalmoscope with retinal drawing	379	$20,253	$20
Return visit (30+ min)	154	$17,591	$77
Destruction of leaking blood vessels of retina using laser	27	$14,585	$275
Destruction of growth of retina using a laser	21	$9,749	$424
Photography of the retina	159	$9,305	$49
Established patient problem focused exam of visual system	78	$8,567	$70
Exam of retinal blood vessels using a special camera after injection of a dye	124	$8,430	$57
2d ultrasound scan of eye tissue and structures	27	$2,778	$75
New patient complete exam of visual system	17	$1,965	$116
Examination of eye by ophthalmoscope with retinal drawing	58	$1,940	$21

2016: 18 services

Sort by

Original Medicare services billed in 2016

Injection, aflibercept, 1 mg	33	$128,772	None
Established patient complete exam of visual system	465	$101,095	$101
Injection, ranibizumab, 0.1 mg	21	$100,931	None
Injection of drug into eye	151	$48,531	$87
Exam of retinal blood vessels using a special camera after injection of a dye	222	$42,948	$70
Imaging of retina	542	$42,707	$29
Injection, bevacizumab, 10 mg	90	$20,226	None
Examination of eye by ophthalmoscope with retinal drawing	382	$18,504	$22
Return visit (30+ min)	106	$13,472	$92
Photography of the retina	193	$13,155	$49
Destruction of growth of retina using a laser	19	$10,896	$454
Destruction of leaking blood vessels of retina using laser	23	$9,975	$293
Established patient problem focused exam of visual system	101	$9,499	$67
2d ultrasound scan of eye tissue and structures	26	$4,017	$80
New patient complete exam of visual system	33	$3,947	$120
Examination of eye by ophthalmoscope with retinal drawing	90	$3,573	$23
Compounded drug, not otherwise classified	20	$1,280	None
Short return visit (20+ min)	11	$442	$40

2015: 22 services

Sort by

Original Medicare services billed in 2015

Established patient complete exam of visual system	285	$36,163	$100
Injection, aflibercept, 1 mg	20	$35,013	None
Injection of drug into eye	138	$32,809	$85
Imaging of retina	382	$29,324	$30
Established patient problem focused exam of visual system	175	$26,616	$70
Destruction of leaking blood vessels of retina using laser	15	$12,832	$855
Exam of retinal blood vessels using a special camera after injection of a dye	70	$12,073	$91
Unclassified biologics	37	$9,510	None
Injection, bevacizumab, 10 mg	57	$9,247	None
Examination of eye by ophthalmoscope with retinal drawing	168	$8,777	$21
Destruction of growth of retina using a laser	15	$7,447	$438
New patient complete exam of visual system	45	$5,386	$120
Photography of the retina	81	$5,027	$62
Examination of eye by ophthalmoscope with retinal drawing	78	$2,985	$23
Compounded Drug, Not Otherwise Classified	32	$2,838	$55
2d ultrasound scan of eye tissue and structures	23	$2,257	$81
Initial nursing facility care with moderate level of medical decision making, per day at least 35 minutes	17	$1,881	$111
New patient problem focused exam of visual system	28	$1,774	$63
Subsequent nursing facility care with straightforward level of medical decision making, per day 20 minutes or more	20	$1,226	$58
Short return visit (20+ min)	15	$996	$59
Examination of eye by ophthalmoscope with retinal drawing	16	$563	$18
Examination of eye by ophthalmoscope with retinal drawing	16	$524	$16

2014: 15 services

Sort by

Original Medicare services billed in 2014

Established patient complete exam of visual system	133	$22,219	$107
Injection of drug into eye	95	$18,434	$88
Exam of retinal blood vessels using a special camera after injection of a dye	94	$18,072	$91
Destruction of leaking blood vessels of retina using laser	15	$14,921	$878
New patient complete exam of visual system	120	$14,918	$124
Imaging of retina	203	$14,897	$37
Established patient problem focused exam of visual system	152	$14,232	$73
Unclassified biologics	53	$10,204	None
Examination of eye by ophthalmoscope with retinal drawing	166	$8,307	$22
Photography of the retina	91	$5,818	$61
Examination of eye by ophthalmoscope with retinal drawing	126	$5,546	$24
2d ultrasound scan of eye tissue and structures	39	$4,800	$81
Injection, bevacizumab, 10 mg	46	$3,961	None
Return visit (30+ min)	23	$2,390	$82
New patient visit (45+ min)	11	$1,432	$130

2013: 11 services

Sort by

Original Medicare services billed in 2013

Return visit (30+ min)	79	$9,150	$87
Injection of drug into eye	53	$6,639	$83
Exam of retinal blood vessels using a special camera after injection of a dye	38	$6,377	$94
New patient complete exam of visual system	46	$5,832	$127
Established patient problem focused exam of visual system	61	$5,042	$74
Examination of eye by ophthalmoscope with retinal drawing	129	$4,849	$21
Photography of the retina	66	$4,745	$62
Injection, bevacizumab, 10 mg	47	$3,438	None
Imaging of retina	68	$2,901	$39
Established patient complete exam of visual system	24	$2,601	$108
Examination of eye by ophthalmoscope with retinal drawing	57	$2,446	$23

Medicaid work

$244,085 in 2024

Medicaid paid $244,085 for 13,206 billed services this clinician did in 2024, up to 120 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Sort by

Largest Medicaid services in 2024

Intravitreal injection of a pharmacologic agent (separate procedure)	1,191	$96,070
Return visit (30+ min)	2,079	$42,995
Injection, bevacizumab, 10 mg	1,210	$35,792
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	2,319	$24,639
New patient visit (45+ min)	320	$17,984
FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT	528	$7,981
Short return visit (20+ min)	434	$6,600
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve	131	$2,924
OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST	97	$2,883
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST	130	$2,752
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient	72	$1,183
Visual field examination, unilateral or bilateral, with interpretation and report; extended examination (eg, Goldmann visual fields with at least 3 isopters plotted and static determination within the central 30°, or quantitative, automated threshold perimetry, Octopus program G-1, 32 or 42, Humphrey visual field analyzer full threshold programs 30-2, 24-2, or 30/60-2)	47	$1,061

Sort by

Medicaid work by year

2024	13,206	20	120	$244,085
2023	11,380	20	152	$343,794
2022	10,901	24	161	$280,392
2021	7,845	20	116	$221,739
2020	4,241	7	81	$153,179
2019	2,945	6	72	$70,788
2018	2,231	6	55	$34,610

See the largest Medicaid services in earlier years

2023

Sort by

Largest Medicaid services in 2023

Intravitreal injection of a pharmacologic agent (separate procedure)	1,074	$183,339
Return visit (30+ min)	2,053	$50,488
Injection, bevacizumab, 10 mg	1,099	$37,552
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	2,233	$30,858
FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT	609	$11,158
TREATMENT X10SV RETINOPATHY	39	$7,168
New patient visit (45+ min)	171	$7,102
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient	238	$3,991
Short return visit (20+ min)	239	$3,658
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST	100	$2,893
OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST	168	$2,108
Unclassified biologics	12	$1,920

2022

Sort by

Largest Medicaid services in 2022

Intravitreal injection of a pharmacologic agent (separate procedure)	1,257	$148,835
Return visit (30+ min)	2,153	$42,471
Injection, bevacizumab, 10 mg	935	$34,324
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	2,674	$29,279
New patient visit (45+ min)	208	$7,444
FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT	608	$6,280
Short return visit (20+ min)	211	$3,961
OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST	171	$2,776
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST	147	$2,556
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient	58	$1,133
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve	102	$1,132
Bilateral extended ophthalmoscopy with drawing of optic nerve, with interpretation and report	75	$201

2021

Sort by

Largest Medicaid services in 2021

Intravitreal injection of a pharmacologic agent (separate procedure)	986	$95,434
Injection, bevacizumab, 10 mg	771	$32,279
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	2,082	$24,803
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST	1,471	$22,139
OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST	239	$10,757
Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient	282	$10,024
Return visit (30+ min)	370	$9,306
New patient visit (45+ min)	149	$7,706
FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT	196	$5,049
DETERMINATION REFRACTIVE STATE	246	$1,946
Short return visit (20+ min)	50	$1,050
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; optic nerve	15	$496

2020

Sort by

Largest Medicaid services in 2020

Intravitreal injection of a pharmacologic agent (separate procedure)	634	$89,244
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST	1,245	$23,356
Injection, bevacizumab, 10 mg	428	$22,253
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	1,361	$17,183
Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed; with evidence of retinopathy (DM)	515	$1,143
OPH SVCS MEDICAL XM&EVAL COMPRE NEW PT 1/> VST	46	$0
FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT	12	$0

2019

Sort by

Largest Medicaid services in 2019

Intravitreal injection of a pharmacologic agent (separate procedure)	330	$34,890
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST	905	$17,096
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	1,007	$12,658
Injection, bevacizumab, 10 mg	130	$3,762
Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed; with evidence of retinopathy (DM)	429	$1,375
Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; subsequent	144	$1,007

2018

Sort by

Largest Medicaid services in 2018

Intravitreal injection of a pharmacologic agent (separate procedure)	242	$15,372
OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST	707	$9,276
Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina	769	$7,511
Injection, bevacizumab, 10 mg	131	$1,905
Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed; with evidence of retinopathy (DM)	340	$376
Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; subsequent	42	$170

Drugs they prescribed that Part D paid

$316,994

Pharmacies billed $316,994 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 3,331) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.

2,011 generic and 1,320 brand-name prescriptions · $316,994 in drug cost.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Sort by

Largest Part D drug costs

Restasis	79	$83,846	$1,061
Lumigan	64	$30,321	$474
Xiidra	21	$27,192	$1,295
Cyclosporine	33	$15,576	$472
Prednisolone Acetate	425	$15,419	$36

See all 26 drugs

Sort by

Every Part D drug this clinician prescribed

Restasis	79	$83,846	$1,061
Lumigan	64	$30,321	$474
Xiidra	21	$27,192	$1,295
Cyclosporine	33	$15,576	$472
Prednisolone Acetate	425	$15,419	$36
Rocklatan	37	$12,552	$339
Rhopressa	26	$11,969	$460
Brimonidine	272	$10,670	$39
Latanoprost	922	$9,206	$10
Alphagan P	22	$9,160	$416
Dorzolamide-Timolol	489	$8,630	$18
Simbrinza	25	$6,333	$253
Prolensa	17	$5,859	$345
Brimonidine Tartrate-Timolol	44	$5,200	$118
Travoprost	30	$2,784	$93
Timolol Maleate	262	$2,545	$10
Dorzolamide	115	$1,903	$17
Ketorolac Tromethamine	89	$1,878	$21
Brinzolamide	16	$1,672	$104
Ofloxacin	137	$1,486	$11
Difluprednate	20	$721	$36
Azelastine	27	$394	$15
Eplerenone	11	$364	$33
Moxifloxacin	11	$267	$24
Erythromycin	17	$175	$10
Acyclovir	14	$112	$8

Year by year

Sort by

Part D prescribing by year

2024	3,331	815	0% (0)	40%	$316,994
2023	2,600	809	0% (0)	42%	$300,652
2022	3,120	842	None	44%	$443,469
2021	1,600	455	0% (0)	52%	$158,611
2020	1,477	384	None	47%	$158,757
2019	1,372	353	None	41%	$112,557
2018	1,382	340	None	37%	$109,341
2017	1,187	334	None	None	$103,365
2016	995	308	0% (0)	49%	$90,697
2015	839	246	0% (0)	49%	$62,878
2014	303	103	None	45%	$15,363
2013	70	38	None	29%	$3,284

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 18 drugs

Sort by

Part D drugs prescribed in 2023

Restasis	69	$74,351	$1,078
Lumigan	64	$31,847	$498
Eylea	12	$24,007	$2,001
Latanoprost	777	$17,575	$23
Alphagan P	42	$15,063	$359
Dorzolamide-Timolol	433	$14,492	$33
Cyclosporine	19	$14,413	$759
Prednisolone Acetate	295	$13,624	$46
Brimonidine Tartrate-Timolol	38	$7,550	$199
Travoprost	26	$7,382	$284
Combigan	17	$5,910	$348
Brimonidine	173	$4,205	$24
Timolol Maleate	200	$3,335	$17
Dorzolamide	69	$2,255	$33
Ketorolac Tromethamine	39	$1,363	$35
Ofloxacin	89	$1,316	$15
Erythromycin	28	$306	$11
Ciprofloxacin	24	$259	$11

2022: 25 drugs

Sort by

Part D drugs prescribed in 2022

Restasis	133	$138,514	$1,041
Lumigan	137	$69,614	$508
Latanoprost	869	$23,213	$27
Xiidra	23	$20,288	$882
Alphagan P	56	$18,672	$333
Combigan	47	$16,695	$355
Prednisolone Acetate	328	$15,263	$47
Dorzolamide-Timolol	371	$13,509	$36
Cyclosporine	17	$11,158	$656
Brimonidine Tartrate-Timolol	42	$10,233	$244
Brimonidine	220	$9,195	$42
Rhopressa	16	$8,185	$512
Vyzulta	12	$7,533	$628
Travoprost	31	$6,700	$216
Azopt	14	$5,608	$401
Timolol Maleate	306	$5,414	$18
Brinzolamide	16	$4,641	$290
Dorzolamide	108	$3,549	$33
Eplerenone	11	$2,244	$204
Ofloxacin	112	$1,571	$14
Tobramycin-Dexamethasone	13	$1,004	$77
Azelastine	18	$830	$46
Ketorolac Tromethamine	31	$752	$24
Erythromycin	37	$398	$11
Neomycin-Polymyxin-Dexameth	11	$157	$14

2021: 14 drugs

Sort by

Part D drugs prescribed in 2021

Restasis	49	$42,444	$866
Combigan	58	$12,925	$223
Prednisolone Acetate	310	$12,714	$41
Latanoprost	455	$11,397	$25
Lumigan	33	$9,880	$299
Alphagan P	41	$9,122	$222
Dorzolamide-Timolol	171	$7,086	$41
Azopt	11	$3,996	$363
Brimonidine	46	$2,935	$64
Timolol Maleate	116	$1,771	$15
Ofloxacin	117	$1,670	$14
Dorzolamide	25	$810	$32
Erythromycin	28	$374	$13
Ketorolac Tromethamine	15	$333	$22

2020: 13 drugs

Sort by

Part D drugs prescribed in 2020

Restasis	55	$58,052	$1,055
Alphagan P	55	$13,305	$242
Lumigan	42	$12,438	$296
Combigan	51	$11,687	$229
Prednisolone Acetate	254	$10,525	$41
Latanoprost	462	$7,600	$16
Dorzolamide-Timolol	113	$4,967	$44
Durezol	23	$4,663	$203
Dorzolamide	43	$1,550	$36
Ofloxacin	99	$1,271	$13
Timolol Maleate	109	$1,211	$11
Brimonidine	61	$1,208	$20
Erythromycin	15	$180	$12

2019: 15 drugs

Sort by

Part D drugs prescribed in 2019

Restasis	39	$31,572	$810
Lumigan	49	$12,726	$260
Combigan	39	$10,800	$277
Prednisolone Acetate	235	$10,066	$43
Travatan Z	29	$8,499	$293
Latanoprost	462	$6,942	$15
Alphagan P	33	$5,895	$179
Durezol	19	$3,952	$208
Dorzolamide-Timolol	64	$3,391	$53
Eplerenone	14	$1,676	$120
Brimonidine	69	$1,566	$23
Timolol Maleate	110	$1,423	$13
Ofloxacin	96	$1,280	$13
Dorzolamide	17	$512	$30
Erythromycin	18	$206	$11

2018: 15 drugs

Sort by

Part D drugs prescribed in 2018

Restasis	40	$23,952	$599
Combigan	68	$13,577	$200
Lumigan	39	$10,840	$278
Latanoprost	509	$7,723	$15
Prednisolone Acetate	165	$7,111	$43
Azopt	13	$6,687	$514
Alphagan P	32	$6,315	$197
Restasis Multidose	12	$6,313	$526
Travatan Z	26	$4,966	$191
Brimonidine	80	$2,038	$25
Eplerenone	12	$1,785	$149
Dorzolamide-Timolol	67	$1,749	$26
Timolol Maleate	122	$1,618	$13
Ofloxacin	90	$1,305	$14
Erythromycin	22	$176	$8

2017: 15 drugs

Sort by

Part D drugs prescribed in 2017

Restasis	46	$30,445	$662
Prednisolone Acetate	186	$8,889	$48
Combigan	32	$8,258	$258
Lumigan	20	$6,292	$315
Travatan Z	37	$6,279	$170
Azopt	12	$6,072	$506
Alphagan P	33	$5,705	$173
Latanoprost	394	$5,446	$14
Eplerenone	14	$2,436	$174
Ofloxacin	107	$2,007	$19
Dorzolamide-Timolol	82	$1,836	$22
Brimonidine	37	$1,336	$36
Ketorolac Tromethamine	15	$654	$44
Timolol Maleate	64	$566	$9
Dorzolamide	11	$256	$23

2016: 18 drugs

Sort by

Part D drugs prescribed in 2016

Restasis	31	$18,135	$585
Lumigan	36	$7,977	$222
Alphagan P	50	$7,415	$148
Prednisolone Acetate	139	$7,096	$51
Patanol	22	$5,398	$245
Brimonidine	50	$4,983	$100
Combigan	26	$4,826	$186
Pataday	15	$4,329	$289
Travatan Z	18	$4,174	$232
Azopt	13	$3,830	$295
Vigamox	16	$2,420	$151
Latanoprost	207	$2,372	$11
Pazeo	15	$2,352	$157
Ketorolac Tromethamine	65	$1,826	$28
Ofloxacin	90	$1,559	$17
Dorzolamide-Timolol	62	$1,476	$24
Timolol Maleate	34	$483	$14
Erythromycin	15	$167	$11

2015: 15 drugs

Sort by

Part D drugs prescribed in 2015

Restasis	29	$12,577	$434
Prednisolone Acetate	161	$8,645	$54
Lumigan	33	$6,043	$183
Travatan Z	23	$4,491	$195
Pataday	21	$3,843	$183
Azopt	11	$3,792	$345
Alphagan P	26	$2,924	$112
Brimonidine	27	$2,401	$89
Ketorolac Tromethamine	70	$1,988	$28
Ofloxacin	94	$1,680	$18
Latanoprost	130	$1,378	$11
Dorzolamide-Timolol	27	$705	$26
Flurbiprofen	48	$384	$8
Erythromycin	21	$331	$16
Timolol Maleate	23	$198	$9

2014: 8 drugs

Sort by

Part D drugs prescribed in 2014

Prednisolone Acetate	64	$3,437	$54
Combigan	12	$1,239	$103
Brimonidine	11	$1,096	$100
Dorzolamide-Timolol	23	$599	$26
Ofloxacin	37	$529	$14
Flurbiprofen	48	$421	$9
Erythromycin	13	$195	$15
Latanoprost	18	$193	$11

2013: 1 drug

Sort by

Part D drugs prescribed in 2013

Ofloxacin	24	$166	$7

Money from drug and device companies

$994 in 2025

Sort by

Industry payments by year

2025	11	26	None	$994
2024	10	40	None	$1,376
2023	12	22	$2,345	$3,374
2022	15	24	$1,620	$3,212
2021	8	24	None	$1,060
2020	4	12	None	$407
2019	9	19	None	$1,026

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

Astellas Pharma US	Izervay	$225	8 payments Meals for Izervay · 2025-12-10 · $33 Meals for Izervay · 2025-10-08 · $20 Meals for Izervay · 2025-09-10 · $34 Meals for Izervay · 2025-07-23 · $34 Meals for Izervay · 2025-05-21 · $32 Meals for Izervay · 2025-04-16 · $22 Meals for Izervay · 2025-02-26 · $26 Meals for Izervay · 2025-01-29 · $23
Alcon Vision	Clareon	$214	5 payments Meals for Tryptyr · 2025-08-12 · $15 Meals for Tryptyr · 2025-07-18 · $24 Meals for Tryptyr · 2025-07-18 · $1 Meals for Clareon · 2025-04-19 · $169 Meals for Rocklatan · 2025-02-26 · $5
Genentech	Susvimo	$140	1 payment Meals for Susvimo · 2025-11-05 · $140
Dompe US	Oxervate	$136	1 payment Meals for Oxervate · 2025-06-12 · $136
Abbvie	Ozurdex	$67	3 payments Meals for Ozurdex · 2025-12-18 · $23 Meals for Ozurdex · 2025-11-03 · $23 Meals for Ozurdex · 2025-05-15 · $21
ANI Pharmaceuticals	Purified Cortrophin Gel	$54	2 payments Meals for Yutiq · 2025-04-23 · $25 Meals for Purified Cortrophin Gel · 2025-01-23 · $29

See all 26 published payments

Sort by

Every published payment

Abbvie	Meals · 2025-12-18	Ozurdex	$23
Astellas Pharma US	Meals · 2025-12-10	Izervay	$33
Harrow Eye	Meals · 2025-11-21	Vevye	$15
Genentech USA	Meals · 2025-11-20	Vabysmo	$32
Genentech	Meals · 2025-11-05	Susvimo	$140
Abbvie	Meals · 2025-11-03	Ozurdex	$23
Astellas Pharma US	Meals · 2025-10-08	Izervay	$20
Glaukos	Meals · 2025-09-23	None	$32
Astellas Pharma US	Meals · 2025-09-10	Izervay	$34
Alcon Vision	Meals · 2025-08-12	Tryptyr	$15
Astellas Pharma US	Meals · 2025-07-23	Izervay	$34
Alcon Vision	Meals · 2025-07-18	Tryptyr	$24
Alcon Vision	Meals · 2025-07-18	Tryptyr	$1
Dompe US	Meals · 2025-06-12	Oxervate	$136
Astellas Pharma US	Meals · 2025-05-21	Izervay	$32
Abbvie	Meals · 2025-05-15	Ozurdex	$21
ANI Pharmaceuticals	Meals · 2025-04-23	Yutiq	$25
Alcon Vision	Meals · 2025-04-19	Clareon	$169
Astellas Pharma US	Meals · 2025-04-16	Izervay	$22
Genentech USA	Meals · 2025-03-17	Vabysmo	$20
Alcon Vision	Meals · 2025-02-26	Rocklatan	$5
Astellas Pharma US	Meals · 2025-02-26	Izervay	$26
Tarsus Pharmaceuticals	Meals · 2025-02-19	Xdemvy	$17
Regeneron Pharmaceuticals	Meals · 2025-02-04	Eylea Hd	$42
Astellas Pharma US	Meals · 2025-01-29	Izervay	$23
ANI Pharmaceuticals	Meals · 2025-01-23	Purified Cortrophin Gel	$29

See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $1,376

Sort by

Payments by company in 2024

Astellas Pharma US	Izervay	$388	11 payments Meals for Izervay · 2024-12-11 · $29 Meals for Izervay · 2024-11-06 · $30 Meals for Izervay · 2024-10-02 · $29 Meals for Izervay · 2024-09-13 · $2 Meals for Izervay · 2024-09-04 · $33 Meals for Izervay · 2024-07-24 · $35 Meals for Izervay · 2024-06-26 · $25 Meals for Izervay · 2024-05-22 · $32 Meals for Izervay · 2024-05-08 · $121 Meals for Izervay · 2024-04-24 · $29 Meals for Izervay · 2024-03-27 · $22
Bausch & Lomb Americas	Stellaris	$265	3 payments Meals for Stellaris · 2024-12-05 · $132 Meals for Miebo · 2024-09-05 · $25 Meals for Stellaris · 2024-03-18 · $108
Abbvie	Ozurdex	$226	12 payments Meals for Ozurdex · 2024-12-12 · $17 Meals for Ozurdex · 2024-12-03 · $6 Meals for Ozurdex · 2024-10-31 · $22 Meals for Ozurdex · 2024-08-29 · $17 Meals for Ozurdex · 2024-08-12 · $26 Meals for Ozurdex · 2024-07-18 · $25 Meals for Ozurdex · 2024-06-13 · $19 Meals for Lumigan · 2024-05-21 · $5 Meals for Ozurdex · 2024-05-09 · $24 Meals for Lumigan · 2024-03-21 · $3 Meals for Ozurdex · 2024-03-18 · $31 Meals for Ozurdex · 2024-02-29 · $29
Genentech USA	Vabysmo	$136	5 payments Meals for Vabysmo · 2024-12-02 · $25 Meals for Vabysmo · 2024-10-09 · $31 Meals for Vabysmo · 2024-06-18 · $25 Meals for Vabysmo · 2024-05-16 · $33 Meals for Vabysmo · 2024-02-22 · $21
Ocular Therapeutix	Dextenza	$131	1 payment Meals for Dextenza · 2024-10-19 · $131
Regeneron Pharmaceuticals	Eylea Hd	$78	1 payment Meals for Eylea Hd · 2024-06-18 · $78
Sun Pharmaceutical Industries	Cequa	$51	2 payments Meals for Cequa · 2024-10-28 · $34 Meals for Cequa · 2024-05-22 · $17
Oyster Point Pharma	Tyrvaya	$37	2 payments Meals for Tyrvaya · 2024-03-06 · $17 Meals for Tyrvaya · 2024-01-03 · $19
Thea Pharma	Iyuzeh	$34	2 payments Meals for Iyuzeh · 2024-04-29 · $17 Meals for Iyuzeh · 2024-02-07 · $18
ANI Pharmaceuticals	Purified Cortrophin Gel	$30	1 payment Meals for Purified Cortrophin Gel · 2024-11-21 · $30

2023: $3,374

Sort by

Payments by company in 2023

Genentech	Susvimo	$2,345	1 payment Consulting for Susvimo · 2023-12-06 · $2,345
Alimera Sciences	Iluvien	$180	4 payments Meals for Iluvien · 2023-12-06 · $16 Meals for Iluvien · 2023-09-13 · $130 Meals for Iluvien · 2023-08-03 · $19 Meals for Iluvien · 2023-05-04 · $15
EyePoint Pharmaceuticals US	Yutiq	$169	2 payments Meals for Yutiq · 2023-02-08 · $29 Meals for Yutiq · 2023-02-07 · $141
Johnson & Johnson Surgical Vision	Catalys System	$130	1 payment Meals for Catalys System · 2023-11-04 · $130
Apellis Pharmaceuticals	Syfovre	$115	3 payments Meals · 2023-11-20 · $53 Meals for Syfovre · 2023-05-11 · $30 Meals for Syfovre · 2023-03-09 · $32
Dompe US	Oxervate	$96	1 payment Meals for Oxervate · 2023-01-25 · $96
Bausch & Lomb Americas	Stellaris	$88	1 payment Meals for Stellaris · 2023-11-21 · $88
Alcon Vision	Argos	$79	3 payments Meals for Argos · 2023-12-20 · $39 Meals for Argos · 2023-09-15 · $14 Meals for Acrysof Iq Vivity · 2023-09-14 · $27
Astellas Pharma US	None	$63	2 payments Meals · 2023-11-06 · $34 Meals · 2023-08-27 · $29
Genentech USA	Vabysmo	$54	2 payments Meals for Vabysmo · 2023-10-26 · $25 Meals for Vabysmo · 2023-05-23 · $29
Regeneron Healthcare Solutions	Eylea Hd	$37	1 payment Meals for Eylea Hd · 2023-12-13 · $37
AbbVie	Ozurdex	$18	1 payment Meals for Ozurdex · 2023-07-05 · $18

2022: $3,212

Sort by

Payments by company in 2022

EyePoint Pharmaceuticals US	Yutiq	$1,933	3 payments Consulting for Yutiq · 2022-08-16 · $1,620 Meals for Yutiq · 2022-07-15 · $147 Meals for Dexycu · 2022-06-14 · $166
Bausch & Lomb Americas	Stellaris	$280	2 payments Meals for Stellaris · 2022-11-04 · $153 Meals for Stellaris · 2022-02-02 · $127
Regeneron Pharmaceuticals	Eylea	$174	2 payments Meals for Eylea · 2022-10-02 · $55 Meals for Eylea · 2022-06-22 · $119
VisionCare	Implantable Miniature Telescope (Imt By Dr. Isaac Lipshitz)	$161	1 payment Meals for Implantable Miniature Telescope (Imt By Dr. Isaac Lipshitz) · 2022-11-16 · $161
Regeneron Healthcare Solutions	Eylea	$160	3 payments Meals for Eylea · 2022-11-05 · $29 Meals for Eylea · 2022-04-01 · $108 Meals for Eylea · 2022-03-18 · $24
Oyster Point Pharma	Tyrvaya	$114	1 payment Meals for Tyrvaya · 2022-06-09 · $114
Dompe US	Oxervate	$84	1 payment Meals for Oxervate · 2022-09-29 · $84
Genentech USA	Susvimo	$70	3 payments Meals for Vabysmo · 2022-12-16 · $22 Meals for Susvimo · 2022-07-21 · $24 Meals for Susvimo · 2022-04-28 · $24
Eyevance Pharmaceuticals	Flarex	$64	1 payment Meals for Flarex · 2022-10-02 · $64
Sun Pharmaceutical Industries	Cequa	$57	2 payments Meals for Cequa · 2022-10-20 · $32 Meals for Cequa · 2022-06-03 · $25
Thea Pharma	None	$43	1 payment Meals · 2022-12-07 · $43
Apellis Pharmaceuticals	None	$23	1 payment Meals · 2022-11-02 · $23
Spark Therapeutics	Luxturna	$20	1 payment Meals for Luxturna · 2022-04-20 · $20
Allergan	Vuity	$16	1 payment Meals for Vuity · 2022-03-17 · $16
Optos	Oct Ophthalmoscope	$13	1 payment Meals for Oct Ophthalmoscope · 2022-05-11 · $13

2021: $1,060

Sort by

Payments by company in 2021

Ivantis	Hydrus Microstent	$530	9 payments Meals for Hydrus Microstent · 2021-10-29 · $122 Meals for Hydrus Microstent · 2021-10-14 · $5 Meals for Hydrus Microstent · 2021-10-14 · $10 Meals for Hydrus Microstent · 2021-10-12 · $24 Meals for Hydrus Microstent · 2021-09-27 · $70 Meals for Hydrus Microstent · 2021-09-27 · $15 Meals for Hydrus Microstent · 2021-08-18 · $24 Meals for Hydrus Microstent · 2021-08-05 · $135 Meals for Hydrus Microstent · 2021-07-02 · $126
Allergan	Ozurdex	$382	7 payments Meals · 2021-12-09 · $115 Meals for Ozurdex · 2021-12-08 · $5 Meals · 2021-11-10 · $115 Meals for Ozurdex · 2021-10-27 · $25 Meals for Ozurdex · 2021-09-23 · $5 Meals · 2021-06-01 · $98 Meals for Ozurdex · 2021-03-19 · $18
Regeneron Healthcare Solutions	Eylea	$72	3 payments Meals for Eylea · 2021-04-22 · $28 Meals for Dupixent · 2021-03-27 · $30 Education for Eylea · 2021-01-06 · $14
Horizon Therapeutics plc	Tepezza	$24	1 payment Education for Tepezza · 2021-11-01 · $24
Genentech USA	Susvimo	$24	1 payment Meals for Susvimo · 2021-12-02 · $24
Aerie Pharmaceuticals	Rhopressa	$14	1 payment Meals for Rhopressa · 2021-10-07 · $14
Eyevance Pharmaceuticals	Zerviate	$13	1 payment Meals for Zerviate · 2021-04-01 · $13
Travere Therapeutics	Cholbam	$1	1 payment Education for Cholbam · 2021-11-29 · $1

2020: $407

Sort by

Payments by company in 2020

Allergan	Ozurdex	$242	6 payments Meals for Ozurdex · 2020-08-17 · $26 Meals for Ozurdex · 2020-06-19 · $20 Meals for Lumigan · 2020-06-13 · $24 Meals for Ozurdex · 2020-03-20 · $22 Meals · 2020-01-27 · $126 Meals for Ozurdex · 2020-01-23 · $24
Regeneron Healthcare Solutions	Eylea	$75	2 payments Meals for Eylea · 2020-10-22 · $38 Meals for Eylea · 2020-08-27 · $37
Aerie Pharmaceuticals	Rhopressa	$46	2 payments Meals for Rhopressa · 2020-09-10 · $21 Meals for Rhopressa · 2020-02-07 · $25
Novartis Pharmaceuticals	Beovu	$44	2 payments Meals for Beovu · 2020-01-30 · $24 Meals for Beovu · 2020-01-15 · $21

2019: $1,026

Sort by

Payments by company in 2019

Allergan	Ozurdex	$604	9 payments Meals for Combigan · 2019-12-11 · $19 Meals · 2019-12-10 · $96 Meals · 2019-10-12 · $108 Meals for Combigan · 2019-09-06 · $15 Meals · 2019-08-14 · $15 Meals · 2019-07-01 · $147 Meals · 2019-03-27 · $116 Meals for Combigan · 2019-02-20 · $22 Meals for Ozurdex · 2019-01-24 · $65
Alcon Vision	Constellation	$143	1 payment Meals for Constellation · 2019-08-07 · $143
EyePoint Pharmaceuticals US	Yutiq	$71	1 payment Meals for Yutiq · 2019-10-12 · $71
Genentech	Lucentis	$54	1 payment Meals for Lucentis · 2019-10-13 · $54
Novartis Pharmaceuticals	Durezol	$45	2 payments Meals for Durezol · 2019-03-20 · $16 Meals · 2019-01-21 · $29
Regeneron Healthcare Solutions	Eylea	$44	2 payments Meals for Eylea · 2019-06-12 · $22 Meals for Eylea · 2019-06-06 · $21
Johnson & Johnson Surgical Vision	Tecnis Symfony Iol	$29	1 payment Meals for Tecnis Symfony Iol · 2019-07-26 · $29
Sun Pharmaceutical Industries	Xelpros	$23	1 payment Meals for Xelpros · 2019-12-30 · $23
Eyevance Pharmaceuticals	Flarex	$13	1 payment Meals for Flarex · 2019-02-21 · $13

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Regeneron Pharmaceuticals, Inc. · A Phase 3b Single-Arm Study of Aflibercept 8 Mg in Participants With Neovascular Age-Related Macular Degeneration (Namd) Or Diabetic Macular Edema (Dme) · 2025	Their institution	$1,085,538
Bayer Healthcare Pharmaceuticals Inc. · Bay865321, Hd 8mg, Amd - Ph 3 · 2023	Their institution	$539,966
Genentech, Inc. · Va2 Phiii Yosemite · 2020	Their institution	$525,358
Bayer HealthCare Pharmaceuticals Inc. · Bay865321 Hd 8mg Amd - Ph 3 · 2021	Their institution	$460,580
Genentech, Inc. · Va2 Phiii · 2020	Their institution	$459,653
Genentech, Inc. · Va2 Phiii · 2021	Their institution	$374,285
Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2020	Their institution	$347,463
Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2021	Their institution	$331,771
Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema · 2021	Their institution	$305,253
Genentech, Inc. · Va2 Phiii Yosemite · 2019	Their institution	$294,130
EyePoint Pharmaceuticals US, Inc. · A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of Eyp-1901, A Tyrosine Kinase Inhibitor (Tki), Compared To Aflibercept in Subjects With Wet Amd · 2024	Their institution	$284,712
Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2022	Their institution	$255,204
Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema · 2022	Their institution	$219,931
Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2022	Their institution	$218,161
EyePoint Pharmaceuticals US, Inc. · A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of Eyp-1901, A Tyrosine Kinase Inhibitor (Tki), Compared To Aflibercept in Subjects With Wet Amd · 2023	Their institution	$203,565
Genentech, Inc. · Ah and Imaging Biomarker Study · 2023	Their institution	$194,441
Bayer Healthcare Pharmaceuticals Inc. · Bay 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration · 2024	Their institution	$185,571
Genentech, Inc. · Va2 Phiii Yosemite · 2021	Their institution	$175,146
Genentech, Inc. · A Phase III Study To Evaluate Faricimab in Patients With Central Retinal Vein Occlusion · 2022	Their institution	$167,662
Genentech, Inc. · Open Label Extension Study To Evaluate the Long Term Safety of Faricimab in Patients With Namd · 2022	Their institution	$160,115
Genentech, Inc. · Va2 Phiii · 2022	Their institution	$155,861
Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2021	Their institution	$147,772
Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema · 2023	Their institution	$147,532
Genentech, Inc. · A Phase III Study To Evaluate Faricimab in Patients With Central Retinal Vein Occlusion · 2023	Their institution	$146,035
Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema · 2025	Their institution	$139,440
Hexal AG · Csok583a12301 · 2022	Their institution	$138,996
Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2023	Their institution	$126,933
Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2024	Their institution	$121,925
Genentech, Inc. · Ah and Imaging Biomarker Study · 2022	Their institution	$115,535
Genentech, Inc. · Open Label Extension Study To Evaluate the Long Term Safety of Faricimab in Patients With Namd · 2023	Their institution	$112,108
Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2020	Their institution	$100,710
Genentech, Inc. · Belvedere · 2024	Their institution	$99,435
Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2021	Their institution	$89,836
Regeneron Pharmaceuticals, Inc. · A Phase 3b Single-Arm Study of Aflibercept 8 Mg in Participants With Neovascular Age-Related Macular Degeneration (Namd) Or Diabetic Macular Edema (Dme) · 2024	Their institution	$86,970
Genentech, Inc. · A Phase III Multicenter Observation Comparator Study of the Efficacy Safety and Pharmacokinetics · 2022	Their institution	$81,589
Genentech, Inc. · A Phase III Multicenter Observation Comparator Study of the Efficacy Safety and Pharmacokinetics · 2021	Their institution	$79,214
Bayer Healthcare Pharmaceuticals Inc. · Bay 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration · 2025	Their institution	$78,162
Ocular Therapeutix, Inc. · Study To Evaluate the Efficacy and Safety of Intravitreal Otx-Tki (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration · 2025	Their institution	$70,832
Genentech, Inc. · Va2 Phiii · 2019	Their institution	$69,545
Genentech, Inc. · A Phase III Multicenter Observation Comparator Study of the Efficacy Safety and Pharmacokinetics · 2025	Their institution	$64,807
Hexal AG · Csok583a12301 · 2023	Their institution	$56,218
Genentech, Inc. · A Phase III Multicenter Observation Comparator Study of the Efficacy Safety and Pharmacokinetics · 2023	Their institution	$54,540
Genentech, Inc. · Study of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema · 2025	Their institution	$52,863
Allergan Inc. · Phase 2 - Evaluation of Abicipar Pegol in Patients With Namd 1771-201-008 · 2019	Their institution	$50,760
Boehringer Ingelheim International GmbH · Crimson: A Multicentre, Randomised, Sham-Controlled (and Active Controlled in the USA), Double-Masked, 72-Week Trial To Study the Safety, Tolerability, Pharmacokinetics, and Efficacy of 3 Dosing Regimens of Intravitreal Bi 764524 in Patients With Moderately Severe To Severe Non-Proliferative Diabetic Retinopathy · 2025	Their institution	$44,667
Bayer HealthCare Pharmaceuticals Inc. · Bay865321, Hd 8mg, Amd - Ph 3 · 2022	Their institution	$38,142
Janssen Research & Development, LLC · A Phase 2/3, Randomized, Double-Masked, Multicenter, Dose-Ranging, Sham-Controlled Clinical Trial To Evaluate Intravitreal Jnj-81201887 (Aavcagscd59) Compared To Sham Procedure for the Treatment of Geographic Atrophy (Ga) Secondary To Age-Related Macular · 2024	Their institution	$37,575
Genentech, Inc. · Va2 Phiii Yosemite · 2022	Their institution	$35,140
Regeneron Pharmaceuticals, Inc. · A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema · 2024	Their institution	$31,401
Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2023	Their institution	$30,919
Genentech, Inc. · A Phase III Study To Evaluate Faricimab in Patients With Branch Retinal Vein Occlusion · 2022	Their institution	$29,356
Bayer Healthcare Pharmaceuticals Inc. · Bay 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 Mg in Macular Edema Secondary To Retinal Vein Occlusion · 2025	Their institution	$29,323
Genentech, Inc. · A Phase III Study To Investigate Ro7200220 in Patients With Uveitic Macular Edema · 2025	Their institution	$28,711
F. Hoffmann-La Roche AG · Real World Long Term Data Collection for Roche Ophthalmology Products Voyager · 2023	Their institution	$28,137
Kyowa Kirin, Inc. · A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study To Assess the Efficacy and Safety of Khk4951, A Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema · 2024	Their institution	$27,600
Genentech, Inc. · Open Label Extension Study To Evaluate the Long Term Safety of Faricimab in Patients With Namd · 2024	Their institution	$27,370
Genentech, Inc. · A Phase III Multicenter Observation Comparator Study of the Efficacy Safety and Pharmacokinetics · 2024	Their institution	$26,864
EyePoint Pharmaceuticals US, Inc. · A Phase 2, Multicenter, Prospective, Double-Masked, Parallel Study of Eyp-1901, A Tyrosine Kinase Inhibitor (Tki), Compared To Sham for the Improvement of Moderately Severe To Severe Nonproliferative Diabetic Retinopathy (Npdr) · 2023	Their institution	$24,149
Novartis Pharmaceuticals Corporation · A 64-Week, Phase 3b, Multi-Center Study Assessing the Efficacy and Safety of Brolucizumab 6mg Compared To Aflibercept 2mg in A Treat To Control Regimen in Patients With Neovascular Age-Related Macular Degeneration · 2021	Their institution	$24,021
Genentech, Inc. · Ah and Imaging Biomarker Study · 2021	Their institution	$23,579
Ocular Therapeutix, Inc. · Study To Evaluate the Efficacy and Safety of Intravitreal Otx-Tki (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration · 2024	Their institution	$23,440
EyePoint Pharmaceuticals US, Inc. · A Phase 2, Multicenter, Prospective, Double-Masked, Parallel Study of Eyp-1901, A Tyrosine Kinase Inhibitor (Tki), Compared To Sham for the Improvement of Moderately Severe To Severe Nonproliferative Diabetic Retinopathy (Npdr) · 2024	Their institution	$19,074
Genentech, Inc. · A Phase III Study To Evaluate Faricimab in Patients With Branch Retinal Vein Occlusion · 2023	Their institution	$18,609
KYOWA KIRIN, INC. · A Phase 2, Multicenter, Randomized, Double-Masked, Parallel Group Study To Assess the Efficacy and Safety of Khk4951, A Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Neovascular Age-Related Macular Degeneration · 2025	Their institution	$16,050
F. Hoffmann-La Roche AG · Real World Long Term Data Collection for Roche Ophthalmology Products Voyager · 2024	Their institution	$14,784
Regeneron Pharmaceuticals, Inc. · A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran Or Cemdisiran Alone in Participants With Geographic Atrophy Secondary To Age-Related Macular Degeneration · 2025	Their institution	$14,468
Janssen Research & Development, LLC · A Phase 2/3, Randomized, Double-Masked, Multicenter, Dose-Ranging, Sham-Controlled Clinical Trial To Evaluate Intravitreal Jnj-81201887 (Aavcagscd59) Compared To Sham Procedure for the Treatment of Geographic Atrophy (Ga) Secondary To Age-Related Macular · 2025	Their institution	$14,037
Roche TCRC, Inc. · A Study To Investigate Ro7200394 As Novel Intravitreal Treatment for Central Retinal Vein Occlusion · 2024	Their institution	$12,405
Genentech, Inc. · Faricimab Dme Long Term Extension Rhone X · 2024	Their institution	$9,880
Allergan Inc. · A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-Related Macular Degeneration · 2019	Their institution	$9,481
EyePoint Pharmaceuticals US, Inc. · A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of Eyp-1901, A Tyrosine Kinase Inhibitor (Tki), Compared To Aflibercept in Subjects With Wet Amd · 2022	Their institution	$9,400
KYOWA KIRIN, INC. · A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study To Assess the Efficacy and Safety of Khk4951, A Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema · 2025	Their institution	$8,868
EyePoint Pharmaceuticals US, Inc. · A Phase 3, Multicenter, Prospective, Randomized, Masked, Controlled, Safety and Efficacy Study of A Fluocinolone Acetonide (Fa) Intravitreal 0.05 Mg Insert (Yutiq 0.05 Mg) in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye · 2023	Their institution	$7,977
Genentech, Inc. · A Phase IV, Multicenter, Open-Label Study To Assess Corneal Endothelial Cells in Patients With Neovascular Age-Related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (Pds) (Belvedere) · 2025	Their institution	$6,450
Genentech, Inc. · Open Label Extension Study To Evaluate the Long Term Safety of Faricimab in Patients With Namd · 2021	Their institution	$6,376
EyePoint Pharmaceuticals US, Inc. · Fluocinolone Acetonide Intravitreal Implant 0.18 Mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis · 2023	Their institution	$5,250
Roche TCRC, Inc. · A Study To Investigate Ro7200394 As Novel Intravitreal Treatment for Central Retinal Vein Occlusion · 2025	Their institution	$4,830
Allergan Inc. · Cognitive Debriefing Interviews for Patient-Reported Outcomes in Dry Eye Disease · 2019	Their institution	$4,312
Boehringer Ingelheim International GmbH · Bi 764524 Phase 2b · 2024	Their institution	$2,867
Genentech, Inc. · A Phase III Study To Evaluate Faricimab in Patients With Central Retinal Vein Occlusion · 2021	Their institution	$2,504
Genentech, Inc. · Open Label Extension Study To Evaluate the Long Term Safety of Faricimab in Patients With Namd · 2025	Their institution	$2,500
ANI Pharmaceuticals, Inc. · The Synchronicity Study · 2025	Their institution	$1,250
Novartis Pharmaceuticals Corporation · A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab Vs. Aflibercept in Patients With Visual Impairment Due To Diabetic Macular Edema (Kingfisher) · 2019	Their institution	$1,030
Allergan, Inc. · A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-Related Macular Degeneration · 2020	Their institution	$1,000
Janssen Research & Development, LLC · Long-Term Extension Study for Participants With Geographic Atrophy (Ga) Secondary To Age-Related Macular Degeneration (Amd) in Jnj-81201887 Parent Clinical Studies · 2025	Their institution	$533
Novartis Pharmaceuticals Corporation · A 64-Week, Phase 3b, Multi-Center Study Assessing the Efficacy and Safety of Brolucizumab 6mg Compared To Aflibercept 2mg in A Treat To Control Regimen in Patients With Neovascular Age-Related Macular Degeneration · 2022	Their institution	$429
Novartis Pharmaceuticals Corporation · A 64-Week, Phase 3b, Multi-Center Study Assessing the Efficacy and Safety of Brolucizumab 6mg Compared To Aflibercept 2mg in A Treat To Control Regimen in Patients With Neovascular Age-Related Macular Degeneration · 2023	Their institution	$64
Bayer Healthcare Pharmaceuticals Inc. · Bay 865321, Aflibercept 8mg in Rvo · 2024	Their institution	$58
Bayer Healthcare Pharmaceuticals Inc. · Aflibercept 8mg in Rvo · 2023	Their institution	$39
Genentech, Inc. · Real World Long Term Data Collection for Roche Ophthalmology Products Voyager · 2024	Their institution	$28

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 100.0 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1205036456
Licence: CA A107595California A107595: Current · expires 2027-03-31
Group: Azul Vision Inc · Eghbali Medical Surgical Inc · North Valley Eye Medical Group Inc · California Eye Specialists Medical Group Inc
Video visits: Lists video visits
Gender: Male

More record details

Sole proprietor: Yes
Taxonomy: Federal specialty code 207WX0107X (207WX0107X); Federal specialty code 207W00000X (207W00000X)
Mailing address: 14726 Ramona Ave Ste 203, Chino, CA, 91710
NPI first listed: 2007-07-24
NPI last updated: 2024-09-23
NPI record certified: 2024-09-23

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 150 S Grand Ave Ste J, Glendora, CA, 91741 · 1845 W Redlands Blvd Ste 101, Redlands, CA, 92373